Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
- 1 May 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (5), 1099-1107
- https://doi.org/10.1128/aac.41.5.1099
Abstract
The anabolism of 1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, a selective inhibitor of human immunodeficiency virus (HIV), was characterized in human T-lymphoblastoid CD4+ CEM cells. 1592U89 was ultimately anabolized to the triphosphate (TP) of the guanine analog (-)-carbovir (CBV), a potent inhibitor of HIV reverse transcriptase. However, less than 2% of intracellular 1592U89 was converted to CBV, an amount insufficient to account for the CBV-TP levels observed. 1592U89 was anabolized to its 59-monophosphate (MP) by the recently characterized enzyme adenosine phosphotransferase, but neither its diphosphate (DP) nor its TP was detected. The MP, DP, and TP of CBV were found in cells incubated with either 1592U89 or CBV, with CBV-TP being the major phosphorylated species. We confirmed that CBV is phosphorylated by 59-nucleotidase and that mycophenolic acid increased the formation of CBV-TP from CBV 75-fold. However, mycophenolic acid did not stimulate 1592U89 anabolism to CBV-TP. The adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) did not inhibit CBV-TP formation from CBV or 1592U89, whereas the adenylate deaminase inhibitor 29-deoxycoformycin selectively inhibited 1592U89 anabolism to CBV-TP and reversed the antiviral activity of 1592U89. 1592U89-MP was not a substrate for adenylate deaminase but was a substrate for a distinct cytosolic deaminase that was inhibited by 29-deoxycoformycin-59-MP. Thus, 1592U89 is phosphorylated by adenosine phosphotransferase to 1592U89-MP, which is converted by a novel cytosolic enzyme to CBV-MP. CBV-MP is then further phosphorylated to CBV-TP by cellular kinases. This unique activation pathway enables 1592U89 to overcome the pharmacokinetic and toxicological deficiencies of CBV while maintaining potent and selective anti-HIV activity.Keywords
This publication has 39 references indexed in Scilit:
- Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivativesInternational Journal of Clinical Pharmacy, 1994
- Mechanisms of Action of Mycophenolic AcidAnnals of the New York Academy of Sciences, 1993
- Metabolism of the carbocyclic nucleoside analog carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cellsBiochemistry, 1990
- Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (−) enantiomerBiochemical and Biophysical Research Communications, 1990
- Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerasesBiochemical and Biophysical Research Communications, 1989
- Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitroBiochemical and Biophysical Research Communications, 1988
- Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminaseBiochemical Pharmacology, 1983
- Inhibitors of adenosine deaminasePharmacology & Therapeutics, 1982
- Adenylate deaminase: Potent inhibition by 2′-deoxycoformycin 5′-phosphateBiochemical and Biophysical Research Communications, 1979
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976